Connect With Us

800-350-8656

9700 Great Seneca Hwy
Rockville, MD 20850

info@3CLogic.com
sales@3CLogic.com
"enhanced reporting"
Not only did we get all the features of our old system with 3CLogic, we got enhanced reporting features that are pictorial, graphical and intuitive.
-Mohit Adalkha,
Assistant General Manager,
Spanco BPO
"endless opportunity"
Since deploying 3CLogic’s Contact Center solution, we are presented with an endless opportunity for business and sales growth.
-Dale McCrary,
VP of Technology,
Sopra Brands
"state of the art product"
3CLogic has come out with a state of the art product that is based on a combination of Cloud Services and Distributed Computing Architecture.
-Alvaro Ramirez,
Cediva

Cloud Call Center Community Featured Article

[June 08, 2004]

Merix Bioscience Launches Trial for New Kidney Cancer Vaccine

DURHAM, N.C. --(Business Wire)-- June 8, 2004 -- Durham-based Merix Bioscience, a company pioneering therapeutic cancer vaccines, announced its first corporate-sponsored clinical trial, a trial with potential significant impact on the future treatment of kidney (renal) cancer. The trial for an RNA-loaded autologous dendritic cell vaccine is now in Phase I/II study at five clinical sites in the United States and Canada.


"We have developed a cancer vaccine that harnesses the ability of an individual's immune system to fight disease," said Clint G. (Skip) Dederick, Jr., chairman, president and CEO of Merix. "We strongly believe that by utilizing an individual patient's tumor antigens to create a personalized vaccine, we can induce the broadest possible immune response and maximize the anti-tumor responses."

The Merix trial focuses on patients newly diagnosed with metastatic renal cell cancer. Dr. Fred Miesowicz, acting head of clinical development at Merix, explained that because the vaccine is composed of dendritic cells taken from the patient's body and infused with amplified RNA from the patient's tumor, the RNA-loaded dendritic cell vaccine is personalized for each patient's specific cancer and primes the patient's immune system to recognize and fight the cancer utilizing the full arsenal of tumor-specific targets.

Additionally, Miesowicz says the study will address feasibility issues: "Another study objective includes demonstrating the safety and commercial feasibility of processing dendritic cells at a central manufacturing facility with delivery of the vaccine to multiple clinical sites."

Given the predominance of cancer in the United States, trial investigators are excited by the potential ramifications of such a vaccine's development.

"Next to heart disease, cancer is the leading cause of death in the United States," said Michael Wong, M.D., Ph.D., FRCPC, medical director of clinical drug development at Roswell Park Cancer Institute in Buffalo, NY, one of the trial sites and one of the nation's leading cancer treatment centers. "For the more than 30,000 people diagnosed with renal cancer each year, the goal of clinical trials, such as this one, is to make available more effective and more tolerable treatment options."

So far, based on encouraging early-stage clinical studies performed at Duke University, investigators for the trial have positive expectations and anticipate the availability of initial results early next year.

Jennifer Knox, M.D., principle investigator and oncologist at Princess Margaret Hospital at the University of Toronto, Canada, is currently treating a patient with the Merix vaccine. "The patient will be treated until progression," said Knox. "We're excited about the potential ability to use the body's immune system to combat kidney cancer tumors. Our first patient is tolerating the vaccination injections well."

World-renowned expert Ralph Steinman, M.D., professor at The Rockefeller University, maintains that dendritic cells serve as the 'eyes and ears' of the body's immune system and by learning to control the power of the cells, you can increase the ability to treat disease. Steinman, who discovered the dendritic cell in 1973, equates the dendritic cell as the link between the outside world and the body's protectorate.

"Dendritic cells amplify potential therapeutic strategies as they deal with harmful agents and orchestrate the body's immune responses. Without the dendritic cell, the immune system is a powerful machine but without controls. Our growing knowledge of this cell has greatly enhanced the capacity to develop immune-based therapies," Steinman said.

Merix Bioscience, Inc. - a privately held company headquartered in Durham, North Carolina, and with additional operations in Erlangen, Germany - is dedicated to becoming a market leader in the field of immunotherapy. Utilizing proprietary technology and proven therapeutic methods and expertise in dendritic cell biology, Merix is developing the next generation of therapies in the areas of oncology, infectious diseases, autoimmune disorders and transplantation. Merix's initial total tumor RNA-loaded dendritic cell vaccine is currently in a corporate Phase I/II clinical trial for patients with metastatic renal cell carcinoma.

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Merix's technology constitute forward-looking statements involving risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, reliance on collaborators, need for additional capital, need for regulatory approvals or clearances, and the maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements.

[ Back To Homepage ]

Resources

Top 5 Disadvantges of Outsourcing
All businesses alike, no matter what goods and services they provide, strive for 100% customer satisfaction. Any decrease in customer satisfaction rates, whether it is through customer service or product interactions can be detrimental to your company's success.
Read More »
The Five Most Dangerous Mistakes Sales Organizations Make
Studies show that the odds of contacting a lead if called in 5 minutes versus 30 minutes drop 100 times. The odds of qualifying a lead if called in 5 minutes versus 30 minutes drop 21 times.
Read More »
Remote Agents in the Cloud!
As an upcoming business owner, you want to make sure you decrease your costs and boost your profits as much as possible. If you run an in-office call center business, you need to worry about managing agents as well as all of the necessary equipment to administer your leads.
Read More »

Cloud Based Solutions Brochure


areg
Contact Centers Made Simple by 3CLogic

3CLogic News

Online Certification Tests from 3CLogic Enhance Quality Assessments for Contact Center Agents and Managers
November 19, 2011
Launch of new 3CLogic University facilitates business growth with certified Call Center staff. Online tests assess agents’ and managers’ contact center knowledge.
Read More »
3CLogic to Double Efficiency of Contact Centers with the Addition of Blended and Multi-Channel Functionalities
October 26, 2011
3CLogic removes barriers for call centers to move to a cloud based service with multi-channel interactions including email, text, voice, and chat. Call blending in the cloud can increase new revenues for businesses by as much as 40%.
Read More »

White Papers

Hosted Contact Centers
In a contemporary era, communication with global citizens calls for global technologies. This means that the hosted contact centers need costly equipment and solutions that cater to modern day needs. They need to be constantly upgraded to give a satisfying experience to the customers.
Read More »

3CLogic Videos